ELEVĒO
2.6.2020 16:02:12 CEST | Business Wire | Press release
ZOOM International a worldwide leader in omni-channel compliance recording, workforce optimization (WFO), and revenue protection software for contact centers will begin doing business solely as elevēo beginning June 2nd , 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005093/en/
For over 20 years, ZOOM International has been a leading workforce optimization software provider in the contact center industry. Very early on, we were approached to solve a compliance problem with call recording. We built a creative software solution in record time, and began a journey crossing continents, employing hundreds of colleagues, and eventually improving operations, compliance, and customer experience for thousands of customers in 94 countries via more than 550 channel partners in the communications industry.
Over time we have earned an 88 NPS score from ZOOM International customers & partners for our world-class support and innovative WFO products. We believe this is a direct result of our core purpose; to create great customer experiences and serve the needs of others: employees, partners & end users. The ZOOM International brand has served us well.
So, why change brands now? As with all strategic business initiatives, there are many reasons, but here are the most impactful:
- Our software platform strategy has culminated in a new native cloud foundation for our products, opening-up new services, products, pricing, and subscription models. With new, improved platform and product capabilities, we felt it deserved a fresh name and look.
- Moreover, we are dedicated to constant improvement. Our mission is to elevate every encounter, which directly focuses on elevating employee engagement, elevating the customer experience and of course increasing the efficiency of each and every channel interaction with a distinct focus on compliance.
The company we created 20 years ago is a very different company than we are today. We are adapting to new business and market needs, serving a broader audience, and migrating to a subscription & cloud native focused strategy.
Effective June 2nd, 2020 ZOOM International will begin solely doing business under the elevēo brand name. All ZOOM International manufactured software products, and solutions (including OEMs) will be developed, marketed, sold, and supported under the elevēo name. In addition to the name, we will be launching a new software as a service offering the week of August 17th, that we call elevēo as a service which allows customers to subscribe to elevēo products without the burden of hosting them and with lower upfront cost.
Perhaps the reasons are best said from our CEO Brian Shore: “We are delighted to announce our new name and brand – Eleveo! Eleveo is closely connected to the Latin word elevo which translates to lift up or to raise. When we think about our mission and how we genuinely wish to serve others. When we think about our products and solutions and the problems we solve. We felt Eleveo in one word universally defines our brand, our culture and our passion to serve others!”
While our name has changed, our culture will not! Serving the needs of others and elevating every encounter is our brand promise! We will continue to innovate, offer greater flexibility, and do business your way as elevēo.
ABOUT ZOOM International
ZOOM guides contact centers toward increased revenue and decreased customer attrition by elevating every customer encounter. Our software captures customer sentiment, providing a true north to guide contact centers in the measurement of people, processes, technologies and assets.
To date ZOOM has helped over 2200 customers and partners worldwide, ranging from sub-100 agent contact centers to brands like Amerigas, IBM, Homecredit, Finansbank, Tata Sky, Generali, Allianz, and Vodafone spanning 90 Countries. More information can be found at zoomint.com or on Twitter @zoomint .
About Elevēo
Elevēo was formed to provide simplified solutions for complex contact center problems. Our products provide only features needed to elevate contact center operations & processes, are built using modern frameworks and cloud native technologies to scale or be hosted anywhere. Elevēo products are birthed from ZOOM International with its rich WFO history, award-winning products, exceptional delivery & reputation for world-class service.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005093/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom